|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
UNDER CONSTRUCTION | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Sunday, November 05, 2006
New Patents for MS Meds
...Also receiving patents was the University of Alberta for BioMS Medical’s synthetic peptide therapeutic, MBP8298, in the U.S. for the treatment of MS. Entitled "Methods of predicting therapeutic efficacy of treatment of a multiple sclerosis patient", the patent addresses techniques to predict efficacy of particular MS therapies. BioMS Medical licenses these patents on an exclusive worldwide basis from the University of Alberta. |